- Home
- GCMG vs ZVRA Comparison
GCMG vs ZVRA Comparison
Compare GCMG & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCMG | ZVRA |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.5M | 499.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCMG | ZVRA |
|---|---|---|
| Price | $11.45 | $8.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $15.25 | ★ $21.71 |
| AVG Volume (30 Days) | 678.3K | ★ 919.3K |
| Earning Date | 02-09-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.32 | ★ 0.54 |
| Revenue | ★ $543,085,000.00 | $84,388,000.00 |
| Revenue This Year | $6.58 | $333.25 |
| Revenue Next Year | $9.84 | $43.70 |
| P/E Ratio | $35.59 | ★ $16.41 |
| Revenue Growth | 17.40 | ★ 244.60 |
| 52 Week Low | $10.23 | $6.19 |
| 52 Week High | $14.48 | $13.16 |
Technical Indicators
Market Signals| Indicator | GCMG | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 53.93 |
| Support Level | $11.31 | $8.01 |
| Resistance Level | $11.64 | $9.01 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 54.78 | 83.50 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.